CAR-T VS TIL
THERAPY
Two cellular therapies, two different biologies. CAR-T engineers synthetic receptors for blood cancers; TIL expands natural tumour-fighting cells for solid tumours.
analyticsAt a Glance
- check_circleCAR-T uses genetically engineered T-cells with a synthetic receptor targeting a specific antigen
- check_circleTIL therapy uses naturally reactive T-cells extracted from the tumour itself
- check_circleTIL therapy may work in tumours without a single dominant antigen โ an advantage in solid cancers
- check_circleBoth are intensive inpatient treatments requiring specialist oncology centre infrastructure
Different Biology, Different Cancers
CAR-T takes T-cells from blood and engineers them with a synthetic receptor designed to lock onto a specific cancer protein. TIL extracts T-cells already inside the tumour โ cells that naturally recognise the cancer โ and expands them from millions into billions. CAR-T is for blood cancers. TIL therapy broke through in solid tumours.
โCAR-T cells carry a new, designed receptor. TIL cells are natural immune cells that already recognise the cancer.โ
CAR-T vs TIL Therapy
CAR-T Cell Therapy
- Engineered synthetic receptorDesigned in a lab to target CD19, BCMA, or other specific antigens.
- Approved for blood cancersB-cell lymphomas, B-ALL, multiple myeloma.
- Single-antigen targetingHigh specificity but vulnerable to antigen escape.
- Blood draw (leukapheresis)No surgery required for cell collection.
TIL Therapy
- Natural tumour-recognising cellsAlready infiltrated the tumour; expanded in the lab.
- First approved solid tumour cell therapyAmtagvi (lifileucel) for advanced melanoma (2024).
- Multi-antigen recognitionTargets multiple tumour antigens simultaneously.
- Requires tumour surgeryBiopsy or resection needed to harvest TILs.
Detailed Comparison
| Factor | CAR-T | TIL Therapy |
|---|---|---|
| Cell source | Patient blood (leukapheresis) | Patient tumour tissue (surgery) |
| Receptor | Synthetic (engineered) | Natural (already present) |
| Target antigens | Single (CD19, BCMA) | Multiple (polyclonal) |
| Approved cancers | Blood cancers | Advanced melanoma |
| Resistance mechanism | Antigen escape (20-30%) | TME suppression |
| Manufacturing time | 3-5 weeks | 3-5 weeks |
Frequently Asked Questions
CAR-T vs TIL
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Understand Which Cellular Therapy Applies to You?
Upload your reports for a specialist evaluation to determine whether CAR-T or TIL therapy is relevant to your diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.